Microbot Medical targets $4M in 2026 revenue with the LIBERTY robotic system launch and a $1.9 price target after its capital raise. See why MBOT stock is a hold.
MBOT’s main value driver is its LIBERTY robot. This is a disposable, portable endovascular robot that has great potential. LIBERTY showed strong ACCESS-PVI data and now awaits FDA 510(k) clearance for ...
HINGHAM, Mass., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY Endovascular Robotic System, announced that Emory University ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback